
Axi-Cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL
Findings from a retrospective comparative analysis showed that axicabtagene ciloleucel (Yescarta; axi-cel) was associated with higher complete response (CR) rates and reduced disease relapse/progression vs tisagenlecleucel (tisa-cel; Kymriah) in …